93 related articles for article (PubMed ID: 5720700)
1. [The value of AHF-prophylaxis].
Olin P
Lakartidningen; 1968 Mar; 65(10):1031-2 passim. PubMed ID: 5720700
[No Abstract] [Full Text] [Related]
2. Home management of hemophilia A.
Van Eys J
J Tenn Med Assoc; 1971 May; 64(5):407-10. PubMed ID: 5091669
[No Abstract] [Full Text] [Related]
3. Experience with prophylaxis in Sweden.
Nilsson IM
Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
[No Abstract] [Full Text] [Related]
4. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
Lange D; Lazerson J
Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
[No Abstract] [Full Text] [Related]
5. Treatment of hemophilia with glycine-precipitated factor 8.
Abildgaard CF; Simone JV; Corrigan JJ; Seeler RA; Edelstein G; Vanderheiden J; Schulman I
N Engl J Med; 1966 Sep; 275(9):471-5. PubMed ID: 5917942
[No Abstract] [Full Text] [Related]
6. [Rehabilitation of children and young people with hemophilia].
Ahlberg A
Lakartidningen; 1968 Mar; 65(10):1026-8. PubMed ID: 5720698
[No Abstract] [Full Text] [Related]
7. Treatment of hemophilia complicated by inhibitors.
Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
[No Abstract] [Full Text] [Related]
8. Aspects of the management of hemophilia in childhood. Availability of newer concentrates of antihemophilic factor failitates management.
Strauss HS
R I Med J; 1966 Aug; 49(8):466-8. PubMed ID: 5222119
[No Abstract] [Full Text] [Related]
9. [Hemophilia and related diseases, with special reference to therapeutic policy].
Nagao T
Nihon Rinsho; 1974 May; 32(5):993-9. PubMed ID: 4603576
[No Abstract] [Full Text] [Related]
10. [Prophylaxis in hemophilia].
Ortega F; Martin-Villar J; Navarro JL
Sangre (Barc); 1970; 15(3):355-61. PubMed ID: 5486763
[No Abstract] [Full Text] [Related]
11. [Inhibitors suppression in hemophilia A with continued treatment of factor VIII].
Aznar JA; Jiménez C; García I; Martín G; Borrego D; Peiro A; Marty ML
Sangre (Barc); 1982; 27(4A):572. PubMed ID: 6818701
[No Abstract] [Full Text] [Related]
12. The use of porcine factor VIII in Japan.
Yoshioka A; Shima M; Morichika S; Terada S; Fukui H
Semin Hematol; 1994 Apr; 31(2 Suppl 4):26-8. PubMed ID: 7939769
[No Abstract] [Full Text] [Related]
13. Cryoprecipitate in the management of haemophilia in Kenya.
Taylor JR; Ahluwalia NS; Morrison CJ; Kaviti JN; Cardwell CL
East Afr Med J; 1969 Feb; 46(2):121-8. PubMed ID: 5798053
[No Abstract] [Full Text] [Related]
14. Hepatitis C and pasteurised factor VIII and IX concentrates.
Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
[No Abstract] [Full Text] [Related]
15. The use of porcine factor VIII in France.
Negrier C
Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770
[No Abstract] [Full Text] [Related]
16. [Safe and cost-conscious supply of factor-VIII-deficient Swiss hemophiliacs with AHF preparations].
Stampfli K
Ther Umsch; 1977 Oct; 34(10):717-24. PubMed ID: 918896
[No Abstract] [Full Text] [Related]
17. [Cases of hemophilia in the Karolinska Hospital Pediatric Clinic].
Dohlwitz A
Lakartidningen; 1968 Mar; 65(10):1033-6. PubMed ID: 5720701
[No Abstract] [Full Text] [Related]
18. Prophylaxis vs. episodic treatment to prevent joint disease in severe hemophilia.
Bernstein MJ
N Engl J Med; 2007 Nov; 357(20):2087; author reply 2087-8. PubMed ID: 18003967
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.
Steele MR; Nagel K; Chan AK
Haemophilia; 2014 Jan; 20(1):e100-1. PubMed ID: 24251412
[No Abstract] [Full Text] [Related]
20. Prophylaxis in children with hemophilia: is it the optimal treatment?
Lusher JM
Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
[No Abstract] [Full Text] [Related]
[Next] [New Search]
